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Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are
approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate
(NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD.
Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the
decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug
mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one
phase to the next. We also reviewed the current AD therapy pipeline.
Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2
trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States
of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S.
than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at
improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of
disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the
number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger
and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate
during the 2002 to 2012 period of 0.4% (99.6% failure).
Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD
therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another
is low, and the number of compounds progressing to regulatory review is among the lowest found in any
therapeutic area. The AD drug-development ecosystem requires support.Introduction
Alzheimer’s disease (AD) is becoming increasingly com-
mon as the global population ages. It is estimated that
currently 44 million victims of AD dementia exist in the
world and that this will grow to more than 100 million
cases by 2050 [1,2]. We urgently need to identify drugs
that prevent, delay the onset, slow the progression, or
improve the symptoms of AD.
Drug development for AD has proven to be very difficult.
Five drugs are approved for the treatment of AD including
four cholinesterase inhibitors (tacrine, donepezil, rivastig-
mine, galantamine) and an N-methyl-D-aspartate (NMDA)* Correspondence: cumminj@ccf.org
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2014receptor AD antagonist (memantine) [3,4]. No new
treatments have been approved for AD since 2003. Tacrine
was approved by the US Food and Drug Administration
(FDA) in 1993, donepezil in 1996, rivastigmine in 1998,
galantamine in 2001, and memantine in 2003 (made avail-
able in the United States in 2004). Many failures in AD drug
development have occurred, with both small molecules and
immunotherapies failing to show a drug/placebo difference
or having unacceptable toxicity [5-8].
To understand better the process of drug development
for AD, we conducted an analysis of clinicaltrials.gov, a
government website that serves the mandate to record
all ongoing clinical trials. We analyzed both trial activity
and, where possible, unique compound progress through
the AD pipeline. We examined all trials since 2002 and
conducted a separate analysis of currently ongoing trialstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Overview of Alzheimer’s disease clinical trials
from clinicaltrials.gov
Year registered Phase 1 Phase 2 Phase 3 Total
2002 0 2 3 5
2003 0 5 7 12
2004 1 9 4 14
2005 4 19 9 32
2006 5 14 6 25
2007 16 22 8 46
2008 25 27 9 61
2009 28 30 14 72
2010 16 24 11 51
2011 15 26 4 45
2012 14 28 8 50
Total 124 206 83 413
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ine historic trends to help understand why AD treatment
development efforts so often fail and to provide insight
into AD drug development.
Methods
Clinicaltrials.gov is a public website that records ongoing
clinical trials of all diseases. The database began in 2000 [9].
In 2005, the International Committee of Medical Journal
Editors (ICMJE) began to require trial registration in a pub-
lic database as a condition of publication [10]. This greatly
increased the number of registrants on clinicaltrials.gov.
Beginning in 2007, the FDA Amendments Act required
registration of all clinical trials of drugs and devices sub-
ject to FDA regulation [11]. Registration is required no
later than 21 days after enrollment of the first partici-
pant. Clinicaltrials.gov provides reliable data on clinical
trials starting from this 2007 date.
Clinicaltrials.gov provides comprehensive information in
text form about trials. The description includes trial name,
sponsor, name of agent, phase of trial, inclusion and exclu-
sion criteria, primary and secondary outcomes, number of
participants, duration of trial, and location of trial sites.
We used the advanced-search mechanisms of clini-
caltrials.gov to construct a comprehensive database
that included the year the trial was registered, phase of
trial (1,2,3), funder, drug name, clinical trials identification
number, study type, status of the trial (active, not recruiting,
recruiting, completed, terminated), date last updated, study
start date, study estimated end date, number of participants
to be enrolled, length of treatment intervention, location
of study (U.S. only, non-U.S. only, both U.S. and non-U.S.),
Mini Mental State Examination (MMSE) score inclusion
criteria, AD condition (cognitively normal persons in pre-
vention trials, prodromal AD, mild cognitive impairment
(MCI), AD dementia), sponsor, allocation (randomized
or not), end-point classification (safety, efficacy, and
so on), intervention model (single group, parallel group,
cross-over), masking (double-blind, open label), and of-
ficial title of trial.
Funders were analyzed as industry, National Institutes
of Health (NIH), NIH plus industry, other federal agen-
cies (such as Department of Veterans Affairs), and all
others (including academic medical centers). Mechanism
of action was also recorded for each agent as: symptomatic
treatment for cognition, symptomatic treatment for
behavior, disease-modifying small molecule, disease-
modifying immunotherapy, therapeutic device, and
stem cells. The category of disease-modifying therapy
with small molecules was further divided into amyloid-
beta (Aβ) protein approaches, tau-related treatments,
and neuroprotective strategies.
Mechanism of action was determined by published data
on the compound. Some compounds have more than oneactivity and were categorized based on what the literature
suggests is the primary mode of action.
Data were analyzed for the decade from 2002 through
2012. Registration on clinicaltrials.gov was not mandated
until 2007, and participation was greatly increased in
2005 by the decision of the ICMJE to require registration
for publication. Data prior to 2007 may be incomplete.
In addition, some Phase 1 studies are conducted out-
side the United States and may not be registered on
clinicaltrials.gov. The 2005 decision by the ICMJE and
the 2007 decision by the FDA caused, somewhat artifi-
cially, increases in the number of trials registered in
those years, because ongoing trials were registered re-
gardless of study-initiation date.
In addition, we conducted an analysis of the currently
active AD-treatment pipeline (end date, February 28, 2014).
This included all agents that are currently registered as
active but not yet recruiting, recruiting, or ongoing but
not currently recruiting.
We excluded all trials of currently approved medications
aimed at supporting the efficacy of an approved compound.
We included trials of currently approved medications if the
trial included an unapproved test agent that was being used
in combination with an approved agent or the approved
agent served as an active comparator.
This is a trend analysis aimed at understanding the
characteristics and trajectory of change over time in AD
drug development, as well as trends across phases and
mechanistic categories of AD candidate therapies. Two-
sample t tests were used to compare trial durations and
sample sizes in Phase 2 and Phase 3.
Results
Table 1 provides an overview of the total number of tri-
als registered over the decade of 2002 through 2012 on
clinicaltrials.gov. The 413 trials include 124 Phase 1
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trials represent 244 unique compounds, with many com-
pounds having more than one trial and some present in
more than one phase. More Phase 2 trials were conducted
than any other trial type, and fewer Phase 3 trials. Taking
the years since 2007 when registration was required, 157
Phase 2 trials and 54 Phase 3 trials were performed. The
total number of trials was highest in 2008 (61) and 2009
(72) and has remained approximately stable (45 to 51)
over the past 3 years.
The pharmaceutical industry sponsors the vast majority
of clinical trials for AD drug development. Seventy-eight
percent of trials (322 of 413) were funded exclusively by
industry, and an additional eight were funded by combina-
tions of NIH ands industry. NIH accounted for 28 (6.7%)
of 413 trials, and other organizations such as academic
medical centers accounted for 55 of 413.
The United States remains the single world region re-
sponsible for most clinical trials (180 (47%) of 385 trials
for which the location was recorded on clinicaltrials.gov.)
However, cumulatively, more trials are now conducted in
international locations (including the U.S. and non-U.S. or
exclusively in non-U.S. sites than in the United States only).
The proportion of U.S. and non-U.S. trials has remained
approximately stable since 2007.
Table 2 presents the trials according to the mechanism
of actions of drugs from 2002 through 2012. The lar-
gest number of registered trials has been conducted
for symptomatic agents aimed at improving cognition
(151 of 413 (36.5%)). The next-largest category is disease-
modifying small molecules (145 (35.1%) of 413) followed
by disease-modifying immunotherapies (76 (18.4%) of 413).
Taken together, disease-modifying agents accounted for







2002 1 3 0
2003 5 1 4
2004 5 2 6
2005 10 3 16
2006 12 1 8
2007 18 1 17
2008 23 1 18
2009 31 2 19
2010 11 2 23
2011 17 2 17
2012 18 4 17
Total 151 22 145
Percent 36.56 5.33 35.11Approximately the same number of disease-modifying
small molecules have been tested each year since 2007
(17–23). The number of disease-modifying immunother-
apies was highest in 2008 through 2010 (13–17) and de-
clined in 2011 and 2012 (5–6). A small number of medical
devices and stem cells have entered clinical trials. Figure 1
shows the number of trials of cognitive-enhancing-agent
trials and of disease-modifying agents in the 2002 through
2012 period. Table 3 presents the trials for drugs with
varying mechanisms of action by trial phase.
Anti-Aβ therapies have dominated AD clinical trials, with
70 of 146 (combined small molecules and immunotherapies)
compounds being directed against Aβ compared with
13 compounds addressing tau-related mechanisms and
62 compounds assessing neuroprotective approaches.
The duration of planned treatment exposure in a trial
varies by the mechanism of the test agent. In Phase 2,
the mean length of trial was 20.0 weeks for symptomatic
cognitive-enhancing agents, 16.8 weeks for symptomatic
behavior agents, 40 weeks for disease-modifying small
molecules (P < 0.0001 compared with cognitive enhancer),
61.7 weeks for immunotherapies (P < 0.0001 compared
with cognitive enhancer), 7.5 weeks for devices, and
10.8 weeks for stem cells.
The mean length of trials in Phase 3 was 34.6 weeks
for symptomatic cognitive-enhancing agents, 21.0 weeks
for symptomatic behavior agents, 62.1 weeks for disease-
modifying small molecules (P < 0.0001 compared with
cognitive enhancer), 139 weeks for immunotherapies
(P < 0.0025 compared with cognitive enhancer), and
78 weeks for devices. In all categories, Phase 2 trials
were shorter than Phase 3 trials.
The number of patients required for trials is larger










1 0 0 5
0 2 0 12
0 1 0 14
3 0 0 32
4 0 0 25
10 0 0 46
15 4 0 61
17 2 1 72
13 2 0 51
5 3 1 45
8 2 1 50
76 16 3 413
18.40 3.87 0.73 100
Figure 1 Comparison of number of trials of symptomatic cognitive-enhancing agents and of disease-modifying agents in the 2002
through 2012 period.
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of patients was 199.7 for symptomatic cognitive-enhancing
agents, 119.5 for symptomatic behavior agents, 162.61
for disease-modifying small molecules (P = 0.28 compared
with cognitive enhancer), 102 for immunotherapies
(P < 0.001 compared with cognitive enhancer), 32.13 for
devices, and 20 for stem cells.
The mean number or patients included in Phase 3
trials was 313.8 for symptomatic cognitive-enhancing
agents, 215.3 for symptomatic behavior agents, 1,086.0Table 3 Mechanisms of action of drugs currently in Phase 1,
Phase 2, and Phase 3 clinical trials (as of February 27, 2014)
Unique compounds per MoA
(current pipeline 02–27)
Phase 1 Phase 2 Phase 3 Total
Symptomatic for cognition 5 10 10 25
Symptomatic for behavior 2 3 4 9
Disease-modifying small
molecule (amyloid-related)
4 5 1 10
Disease-modifying small
molecule (tau-related)
3 0 1 4
Disease-modifying small
molecule (neuroprotector)
2 19 4 25
Disease-modifying
immunotherapy
4 8 3 15
Therapeutic device 2 4 0 6
Stem cells 0 1 0 1
Total 22 50 23 95for disease-modifying small molecules (P < 0.0001 compared
with cognitive enhancer), 1,321.9 for immunotherapies
(P = 0.068 compared with cognitive enhancer), and 178.5
for devices. In all categories, fewer patients were included
in Phase 2 than in Phase 3 trials.
We examined the progression of compounds from Phase
1 to Phase 2 and from Phase 2 to Phase 3. We reviewed
the percentage of compounds that appeared in Phase 1
and were advanced to Phase 2 and the percentage that
were listed in Phase 2 and then advanced to Phase 3.
Twenty-one compounds that were registered in Phase 1
during the 2002 through 2012 period were also tested in
Phase 2 (28% advance rate; 72% attrition rate). Fourteen
compounds registered in Phase 2 were advanced to Phase
3 and tested during the decade reviewed (8% advance rate;
92% attrition rate). During the decade reviewed, one
compound (memantine) was advanced from Phase 3 to the
FDA for review and approval, and 54 compounds were
tested in Phase 3 during this period (1.8% advance rate;
98.2% attrition rate; for this calculation, we excluded all
current Phase 3 compounds because they may succeed in
advancing to the FDA for review). Overall, 244 compounds
were assessed in the decade of 2002 through 2012 and one
was approved for marketing; excluding the 14 compounds
currently in Phase 3, the success rate for advancing agents
for regulatory approval is 0.4% (99.6% attrition).
We examined the currently active pipeline of AD ther-
apies to understand the characteristics of agents currently
in development (end date as February 28, 2014). Of these,
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Phase 1 trials representing 22 unique therapies; 54 Phase
2 trials assessing 49 unique treatments; and 30 trials Phase
3 testing 23 therapeutic compounds. Phase 3 includes
six cognitive-enhancing agents, four drugs aimed at
improving behavioral symptoms, seven disease-modifying
small molecules, one trial of insulin, and three disease-
modifying immunotherapies.
Discussion
This study used the publically available clinicaltrials.gov
database to assess the historic trends of AD drug develop-
ment and to put the current pipeline of agents in perspec-
tive. The results demonstrate that detailed interrogation of
clinicaltrials.gov can provide insight into longitudinal trends
in drug development. A comprehensive database of all
clinical trials registered in clinicaltrials.gov, the Aggregate of
ClinicalTrials.gov (AACT), has become available [12] and
may facilitate further analyses.
In the decade of 2002 through 2012, 244 compounds
were assessed in 413 trials for AD. Of the agents advanced
to Phase 3 (and excluding those currently in Phase 3), one
was advanced to the FDA and approved for marketing
(1.8%). Excluding the 14 compounds currently in Phase 3,
the overall success rate for approval is 0.4% (99.6% attrition).
This is among the lowest for any therapeutic area [13,14].
The developmental time lines for conducting two Phase
3 trials needed to satisfy FDA requirements is substantially
shorter for symptomatic agents than for disease-modifying
compounds. For symptomatic cognitive enhancers in Phases
2 and 3, the trials were 20 and 34.6 weeks in duration,
whereas trials of disease-modifying agents were 47.6 and
90.9 weeks in Phase 2 and Phase 3, respectively. The total
duration of a trial is the length of time devoted to recruitment
plus the treatment period; in some cases, the trial length in-
cluded an open-label extension. The period of recruitment
varies and is often longer than anticipated by the sponsor, be-
cause recruitment of AD patients is slower than expected for
many trials [15]. The total time that a compound resides in
any phase of the development pathway is a combination of
duration of all the trials performed (some may be done con-
currently) and time for analysis and decision making.
Progression through the pipeline is not necessarily se-
quential. Not all compounds tested in Phase 2 or 3 would
have been assessed in previous stages. For example, a repur-
posed compound could be tested in Phase 3, based on data
generated in populations with other indications, without
necessarily be assessed in Phase 1 or in Phase 2 for AD.
Rosiglitazone is an example of such a compound; it was
tested in Phases 1, 2, and 3 for diabetes and in Phase 3 for
AD. A repurposed compound entering the pipeline in
Phase 3 might require testing in Phase 1 (for example,
drug-drug interactions studies with antidementia agents in
healthy volunteers). Dimebon is an example of this reversesequencing; this agent had simultaneous Phase 1 trials asses-
sing drug-drug interactions and Phase 3 trials for efficacy.
As drugs progress through the development pipeline,
trials become longer and larger; this is especially evident
in the programs for disease-modifying compounds.
The mean duration of trials in Phase 2 is 47.6 weeks,
and the mean duration of Phase 3 is 90.9 weeks. The
average number of patients in Phase 2 is 142, and the
average number in Phase is 833. The resource requirements
for developing disease-modifying agents are greater than
those required for symptomatic agents. Phase 2 has been
substantially smaller and shorter than Phase 3 for most
agents. More-robust Phase 2 programs with better under-
standing of the molecule might contribute to improving the
success rate in Phase 3.
The attrition rate for AD treatment is high, with 72% of
agents failing in Phase 1, 92% failing in Phase 2, and 98%
failing in Phase 3 in the period observed. If these rates are
applied to the current pipeline, 6.4 of the agents in Phase
1 and 4.7 of the agents in Phase 2 will be advanced to the
next stage. Of the 14 drugs currently in Phase 3, the data
predict that only a very limited chance exists of any being
advanced for regulatory review. Predictions of this type
will remain conservative until a breakthrough first-in-class
agent recalibrates the expectations.
The one agent approved during the decade reviewed
(memantine) is a symptomatic cognitive enhancer.
Cognitive-enhancing agents are an active area of in-
vestigation with 151 of 413 trials in the 2002 through
2012 period devoted to this class of agents.
Two-hundred twenty-one agents have been assessed
for disease-modifying potential, and none has shown a
drug-placebo difference in favor of active treatment on
primary outcomes, although a few agents (seven) are in
on-going trials of this class of agent, and their outcome
has yet to be determined. Failures in trials may be based
on lack of efficacy, excessive side effects, or challenges
in trial execution. Trial-conduct failure is suggested by
a lack of decline in the placebo group, no effect in an
active-treatment comparator arm of the study, or excessive
measurement variability. The reasons for trial failures
suggest means of enhancing the success of trials, includ-
ing improved rating strategies, enhanced training, and
better patient-selection approaches [16,17]. New means
of predicting drug toxicity may reduce the attrition rate
attributable to lack of safety [18,19].
Reasons for lack of efficacy in well-conducted trials
must also be interrogated to improve the success rate
for AD drug development. It has been suggested that
use of antiamyloid agents may be optimized by intervening
earlier in the disease process before nonamyloid processes
prevail and neurodegeneration begins [20-23]. Identifying
new disease pathways more amenable to pharmacologic
manipulation, improved understanding of the complex
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may provide new approaches to AD therapy [24-26].
Most disease-modifying trials have some form of Aβ
protein as the pharmacologic target (that is, four of six
current Phase 3 compounds of disease-modifying agents
target the amyloid-beta protein). One-hundred forty-five
(65.6%) of 221 trials of disease-modifying agents registered
in the 2002 through 2012 period were directed at this target.
The target is unvalidated, and no class of agents has shown
efficacy for this target in human clinical trials. Many animal
models of amyloidosis have shown biological and behav-
ioral benefit from anti-Aβ agents, creating a “translational
gap” between human and animal studies [27-30]. De-
velopment of animal models more predictive of success
in human trials, diversification of targets within AD, use of
rational combinations to address multiple disease pathways
simultaneously, and optimizing the selection of patients
more likely to be responsive to antiamyloid therapies may
all enhance success in AD drug development.
The current AD pipeline is relatively modest, given the
enormous challenge posed by this disease. AD is more
expensive to the U.S. economy than cardiovascular dis-
ease or cancer [31]. Currently, 108 clinical trials for AD
therapies are being conducted. This compares with 1,438
ongoing trials for oncology agents. The success rate of
development of oncology compounds is 19% [32], en-
couraging biotechnology and pharmaceutical companies
to invest time, effort, and funds in oncology drug test-
ing. Similar successes are needed to spur AD drug
development.
The high rate of attrition of compounds requires a
constant supply of new approaches (new chemical entities,
immunotherapies, repurposed drugs, devices) that can
be assessed for efficacy in AD. The pipeline is dependent
on a complex drug-development ecosystem of academic
laboratories, federal funding agencies, biotechnology
companies, venture capital, philanthropy, trial sites, con-
tract research organizations, pharmaceutical companies,
advocacy groups, and regulatory agencies. This ecosystem
must be supported, grown, and coordinated to improve
the success of AD trials and development of desperately
needed new AD therapies.
Conclusion
ClinicalTrials.gov provides a remarkable resource of in-
formation regarding drug development for AD and other
disorders. Trends in AD drug development over time
can be seen, and the movement of the drugs through the
pipeline can be monitored. ClinicalTrials.gov has provided
comprehensive information since 2007, when registration
of clinical trials was required by the FDA. The analyses
demonstrate that the number of clinical trials has been de-
clining since the 2008 through 2009 period. The pharma-
ceutical industry sponsors most drug development for AD,whereas NIH accounts for a relatively small percentage of
drug development. The United States has the largest num-
ber of clinical trials of any single country, but more clinical
trials are conducted outside of the United States than in-
side of the United States.
Most trials address symptomatic agents intended to im-
prove cognition, but disease-modifying small molecules
and disease-modifying immunotherapies are also repre-
sented in the drug-development pipeline. More therapies
address amyloid-beta targets than any other single target.
Phase 2 trials are smaller and shorter than Phase 3 trials,
and sponsors have relatively limited experience with most
molecules when they enter Phase 3.
Most drugs entering the AD drug-development pipe-
line have failed; only one agent has been approved
since 2004 (memantine). The failure rate since 2002
(excluding agents currently in Phase 3) is 99.6%. Currently,
108 trials of AD therapies represent 94 unique agents.
This is a relatively small number of test compounds.
The small number of agents in Phase 1 (22) is particu-
larly concerning, as it suggests that relatively few drugs
are entering the AD drug-development process. Repur-
posed agents may enter the pipeline at later phases, but
it is unlikely that a large number of repurposed agents
will be assessed. The AD drug-development pipeline is
relatively small, and the rate of success of AD clinical
trials is limited. An urgent need exists to increase the
number of agents entering the pipeline and progressing
successfully toward new therapy for patients with AD.
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